Table 2.
Studies that report both sarcopenia and myosteatosis and the respective HR for OS
| For OS | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| Study | Sarcopenia (HR, 95% CI) | Myosteatosis (HR, 95% CI) | Sarcopenia (HR, 95% CI) | Myosteatosis (HR, 95% CI) | Combined sarcopenia and myosteatosis (HR, 95% CI) |
| Charette et al. 30 | 2.06 (1.45 to 2.93) | 1.54 (1.09 to 2.18) | 1.49 (1.04 to 2.15) | 1.80 (1.24 to 2.61) | |
| Deng et al. 32 | 0.93 (0.84 to 1.02) | 0.99 (0.95 to 1.04) | NA | NA | |
| Dolan et al. 17 | 1.74 (1.21 to 2.49) | 1.84 (1.25 to 2.72) | 1.50 (1.04 to 2.18) | 1.42 (0.98 to 2.05) | |
| Hopkins et al. 31 | 2.01 (1.67 to 2.50) | 2.03 (1.61 to 2.54) | 1.45 (1.15 to 1.84) | 1.54 (1.19 to 1.98) | 2.24 (1.63 to 3.09) |
| Kroenke et al. 9 | NA | NA | 1.30 (1.07 to 1.57) | 1.63 (1.30 to 2.05) | 2.02 (1.65 to 2.47) |
| Looijaard et al. 33 | 0.953 (0.812 to 1.119) | 0.814 (0.694 to 0.955) | 0.998 (0.840 to 1.187) | 0.918 (0.771 to 1.093) | |
| Malietzis et al. 8 | 1.77 (1.32 to 2.38) | 1.42 (1.09 to 2.50) | 1.70 (1.25 to 2.31) | NA | |
| McSorley et al. 4 | 1.40 (0.88 to 2.24) | 2.47 (1.49 to 4.10) | NA | 2.29 (1.38 to 3.81) | |
| Okugawa et al. 14 | NA | NA | NA | NA | |
| Sabel et al. 34 | NA | 0.97 (0.95 to 1.00) | NA | NA | |
| Sueda et al. 12 | 2.14 (0.99 to 4.97) | 2.42 (1.10 to 5.84) | 2.29 (1.04 to 5.41) | 2.94 (1.32 to 7.17) | |
| Van Baar et al. 28 | NA | NA | NA | 1.91 (1.53 to 2.38) | |
| Van Vugt et al. 29 | 1.35 (1.03 to 1.76) | 1.75 (1.29 to 2.36) | 1.06 (0.80 to 1.42) | 0.91 (0.65 to 1.29) | |
CI, confidence interval; HR, hazard ratio; OS, overall survival; NA, not applicable.